Maximus, Inc. (MMS) Expected to Announce Quarterly Sales of $606.86 Million
Analysts predict that Maximus, Inc. (NYSE:MMS) will report sales of $606.86 million for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Maximus’ earnings, with the lowest sales estimate coming in at $601.09 million and the highest estimate coming in at $615.25 million. Maximus reported sales of $623.09 million during the same quarter last year, which indicates a negative year over year growth rate of 2.6%. The firm is scheduled to issue its next earnings results on Thursday, November 9th.
On average, analysts expect that Maximus will report full-year sales of $606.86 million for the current year, with estimates ranging from $2.43 billion to $2.45 billion. For the next year, analysts forecast that the business will post sales of $2.52 billion per share, with estimates ranging from $2.45 billion to $2.60 billion. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Maximus.
Maximus (NYSE:MMS) last posted its quarterly earnings results on Thursday, August 3rd. The health services provider reported $0.79 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.76 by $0.03. Maximus had a return on equity of 25.08% and a net margin of 8.43%. The business had revenue of $600.40 million for the quarter, compared to analyst estimates of $614.12 million. During the same period last year, the company earned $0.79 EPS. The firm’s revenue was down 2.7% on a year-over-year basis.
Several analysts recently weighed in on MMS shares. KeyCorp reissued a “sector weight” rating on shares of Maximus in a research note on Thursday, May 25th. Canaccord Genuity cut shares of Maximus from a “buy” rating to a “hold” rating and set a $62.00 price objective on the stock. in a research note on Tuesday, July 4th. BidaskClub cut shares of Maximus from a “strong-buy” rating to a “buy” rating in a research note on Thursday, July 6th. Zacks Investment Research cut shares of Maximus from a “hold” rating to a “sell” rating in a research note on Tuesday, July 18th. Finally, Maxim Group set a $66.00 price objective on shares of Maximus and gave the stock a “hold” rating in a research note on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating and nine have assigned a hold rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $62.43.
In other Maximus news, General Counsel David Francis sold 1,000 shares of the company’s stock in a transaction on Friday, June 23rd. The shares were sold at an average price of $63.15, for a total transaction of $63,150.00. Following the sale, the general counsel now owns 16,715 shares of the company’s stock, valued at $1,055,552.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Bruce Caswell sold 8,000 shares of the company’s stock in a transaction on Wednesday, July 12th. The shares were sold at an average price of $62.21, for a total transaction of $497,680.00. Following the sale, the president now directly owns 35,904 shares in the company, valued at approximately $2,233,587.84. The disclosure for this sale can be found here. Insiders have sold 133,403 shares of company stock worth $8,151,491 in the last ninety days. Insiders own 3.10% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. boosted its position in Maximus by 22,491.0% during the first quarter. BlackRock Inc. now owns 6,503,511 shares of the health services provider’s stock valued at $404,518,000 after acquiring an additional 6,474,723 shares during the last quarter. Vanguard Group Inc. boosted its position in Maximus by 2.4% during the second quarter. Vanguard Group Inc. now owns 5,669,026 shares of the health services provider’s stock valued at $355,052,000 after acquiring an additional 130,839 shares during the last quarter. FMR LLC boosted its position in Maximus by 10.4% during the second quarter. FMR LLC now owns 4,658,584 shares of the health services provider’s stock valued at $291,767,000 after acquiring an additional 438,025 shares during the last quarter. William Blair Investment Management LLC boosted its position in Maximus by 14.7% during the first quarter. William Blair Investment Management LLC now owns 4,416,279 shares of the health services provider’s stock valued at $274,693,000 after acquiring an additional 566,292 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its position in Maximus by 8.6% during the second quarter. Victory Capital Management Inc. now owns 3,100,903 shares of the health services provider’s stock valued at $194,210,000 after acquiring an additional 244,823 shares during the last quarter. 97.23% of the stock is currently owned by institutional investors and hedge funds.
Maximus (MMS) traded down 0.76% on Friday, hitting $62.81. The stock had a trading volume of 253,504 shares. Maximus has a 12-month low of $43.69 and a 12-month high of $64.97. The company has a 50 day moving average of $60.88 and a 200 day moving average of $61.50. The company has a market capitalization of $4.07 billion, a PE ratio of 20.13 and a beta of 1.37.
The company also recently declared a quarterly dividend, which was paid on Thursday, August 31st. Shareholders of record on Tuesday, August 15th were given a dividend of $0.045 per share. The ex-dividend date of this dividend was Friday, August 11th. This represents a $0.18 dividend on an annualized basis and a yield of 0.29%. Maximus’s dividend payout ratio (DPR) is currently 5.73%.
Maximus Company Profile
MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.